I’d expect significant redundancy costs to form part of H1 results, the wages piece won’t make for happy reading and potentially EBITDA % at its lowest performance ebb.
However now with a more streamlined management structure, Apiam might start to achieve a better yield if revenue per Vet is on the rise, assuming it’s been able to obtain quality income generating Vets for its clinic network. H2 might see the start of a positive recovery. Watch this space.
- WE.
I’d expect significant redundancy costs to form part of H1...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
-0.020(3.88%) |
Mkt cap ! $91.05M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 52.0¢ | 49.5¢ | $79.40K | 156.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 81288 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 25575 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| AHX (ASX) Chart |